Skip to content

An Algorithm Driven Sepsis Prediction Biomarker

A Randomized Controlled Clinical Trial of an Algorithm Driven Sepsis Prediction Biomarker

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03015454
Enrollment
142
Registered
2017-01-10
Start date
2016-12-31
Completion date
Unknown
Last updated
2021-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, Septic Shock, Severe Sepsis

Keywords

InSight, Dascena

Brief summary

A sepsis early warning predictive algorithm, InSight, has been developed and validated on a large, diverse patient cohort. In this prospective study, the ability of InSight to predict severe sepsis patients is investigated. Specifically, InSight is compared with a well established severe sepsis detector in the UCSF electronic health record (EHR).

Interventions

Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.

Upon receiving information from the severe sepsis detector in the UCSF electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.

Sponsors

University of California, San Francisco
CollaboratorOTHER
Dascena
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All adult patients admitted to the participating units will be eligible.

Exclusion criteria

* All patients younger than 18 years of age will be excluded.

Design outcomes

Primary

MeasureTime frame
Hospital length of stayThrough study completion, an average of 45 days

Secondary

MeasureTime frame
In-hospital mortalityThrough study completion, an average of 45 days

Other

MeasureTime frame
ICU length of stayThrough study completion, an average of 45 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026